神經肌肉阻斷劑(NMBA Neuronmuscular Block Agents)在臨床上的使用
Desirable effects of NMBA infusions We noted important clinical and statistical heterogeneity in the pooled estimate for mortality. Consequently, we did not use the pooled estimate across all studies for mortality to inform the recommendations. Instead, the panel considered the mortality outcome according to the sedation strategy utilized in the control group of included trials. The first subgroup included only the ROSE trial as it was the only trial that aimed to use a lighter sedation strategy for patients in the control arm. The hospital mortality for this subgroup did not favour either the intervention or control [relative risk (RR) 0.99; 95% confidence interval (CI) 0.86–1.15]. The remaining subgroup included 3 trials that aimed to use a deeper sedation strategy for patients in the control arm [14, 15, 19]. In this subgroup, an NMBA infusion reduced hospital mortality (RR 0.72; 95% CI 0.58–0.91) with low certainty. It is possible however, that the heterogeneity in effect may be explained by other differences between the trials
Briefly speaking,考量利弊後
針對急性呼吸窘迫症候群(acute respiratory distress syndrome，簡稱ARDS) 的患者，在以物理手段(高頻通氣法(High frequency ventilation)前可以使用以降低致死風險
嚴重與中度ARDSpt可以使用鎮靜劑(low evidence)，醫師評估可以延長使用至48小時
創作內容
神經肌肉阻斷劑NMBA用於ARDS患者的實證研究
♔--Ragnarok (19)